234 related articles for article (PubMed ID: 36297510)
1. Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment.
Tambunlertchai S; Geary SM; Salem AK
Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297510
[TBL] [Abstract][Full Text] [Related]
2. Anti-melanoma Effects of Resiquimod (RSQ) In Vitro and in Combination with Immune Checkpoint Blockade In Vivo.
Tambunlertchai S; Geary SM; Naguib YW; Salem AK
AAPS J; 2023 Jun; 25(4):57. PubMed ID: 37266761
[TBL] [Abstract][Full Text] [Related]
3. Investigating silver nanoparticles and resiquimod as a local melanoma treatment.
Tambunlertchai S; Geary SM; Naguib YW; Salem AK
Eur J Pharm Biopharm; 2023 Feb; 183():1-12. PubMed ID: 36549400
[TBL] [Abstract][Full Text] [Related]
4. Topical treatment of melanoma skin metastases with imiquimod: a review.
Sisti A; Sisti G; Oranges CM
Dermatol Online J; 2015 Feb; 21(2):. PubMed ID: 25756475
[TBL] [Abstract][Full Text] [Related]
5. Imiquimod-oleic acid prodrug-loaded cream reduced drug crystallinity and induced indistinguishable cytotoxicity and apoptosis in mice melanoma tumour.
Sharma A; Sharma D; Baldi A; Jyoti K; Chandra R; Madan J
J Microencapsul; 2019 Dec; 36(8):759-774. PubMed ID: 31587598
[TBL] [Abstract][Full Text] [Related]
6. Resiquimod: a new topical immune-response modifier for the treatment of actinic keratosis.
Farr MA; Joshi TP; Lewis DJ
Expert Opin Emerg Drugs; 2021 Dec; 26(4):433-434. PubMed ID: 34749552
[TBL] [Abstract][Full Text] [Related]
7. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
Sabado RL; Pavlick A; Gnjatic S; Cruz CM; Vengco I; Hasan F; Spadaccia M; Darvishian F; Chiriboga L; Holman RM; Escalon J; Muren C; Escano C; Yepes E; Sharpe D; Vasilakos JP; Rolnitzsky L; Goldberg J; Mandeli J; Adams S; Jungbluth A; Pan L; Venhaus R; Ott PA; Bhardwaj N
Cancer Immunol Res; 2015 Mar; 3(3):278-287. PubMed ID: 25633712
[TBL] [Abstract][Full Text] [Related]
8.
Caimi AT; Ramirez C; Perez AP; Romero EL; Morilla MJ
Drug Dev Ind Pharm; 2022 Nov; 48(11):657-666. PubMed ID: 36445155
[TBL] [Abstract][Full Text] [Related]
9. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
Bong AB; Bonnekoh B; Franke I; Schön M; Ulrich J; Gollnick H
Dermatology; 2002; 205(2):135-8. PubMed ID: 12218228
[TBL] [Abstract][Full Text] [Related]
10. Topical resiquimod protects against visceral infection with Leishmania infantum chagasi in mice.
Craft N; Birnbaum R; Quanquin N; Erfe MC; Quant C; Haskell J; Bruhn KW
Clin Vaccine Immunol; 2014 Sep; 21(9):1314-22. PubMed ID: 25030052
[TBL] [Abstract][Full Text] [Related]
11. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.
Adams S; O'Neill DW; Nonaka D; Hardin E; Chiriboga L; Siu K; Cruz CM; Angiulli A; Angiulli F; Ritter E; Holman RM; Shapiro RL; Berman RS; Berner N; Shao Y; Manches O; Pan L; Venhaus RR; Hoffman EW; Jungbluth A; Gnjatic S; Old L; Pavlick AC; Bhardwaj N
J Immunol; 2008 Jul; 181(1):776-84. PubMed ID: 18566444
[TBL] [Abstract][Full Text] [Related]
12. The antiviral activity of Toll-like receptor 7 and 7/8 agonists.
Miller RL; Meng TC; Tomai MA
Drug News Perspect; 2008 Mar; 21(2):69-87. PubMed ID: 18389099
[TBL] [Abstract][Full Text] [Related]
13. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.
Swetter SM; Chen FW; Kim DD; Egbert BM
J Am Acad Dermatol; 2015 Jun; 72(6):1047-53. PubMed ID: 25791801
[TBL] [Abstract][Full Text] [Related]
14. Self-assembled mPEG-hexPLA polymeric nanocarriers for the targeted cutaneous delivery of imiquimod.
Lapteva M; Mignot M; Mondon K; Möller M; Gurny R; Kalia YN
Eur J Pharm Biopharm; 2019 Sep; 142():553-562. PubMed ID: 30641138
[TBL] [Abstract][Full Text] [Related]
15. Topical Application of Mesenchymal Stem Cell Exosomes Alleviates the Imiquimod Induced Psoriasis-Like Inflammation.
Zhang B; Lai RC; Sim WK; Choo ABH; Lane EB; Lim SK
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33450859
[TBL] [Abstract][Full Text] [Related]
16. Mediators of Inflammation in Topical Therapy of Skin Cancers.
Voiculescu VM; Lisievici CV; Lupu M; Vajaitu C; Draghici CC; Popa AV; Solomon I; Sebe TI; Constantin MM; Caruntu C
Mediators Inflamm; 2019; 2019():8369690. PubMed ID: 30766448
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effect of Imiquimod enhanced ALA-PDT on cutaneous squamous cell carcinoma.
Bhatta AK; Wang P; Keyal U; Zhao Z; Ji J; Zhu L; Wang X; Zhang G
Photodiagnosis Photodyn Ther; 2018 Sep; 23():273-280. PubMed ID: 30030167
[TBL] [Abstract][Full Text] [Related]
18. Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.
Mauldin IS; Wages NA; Stowman AM; Wang E; Olson WC; Deacon DH; Smith KT; Galeassi N; Teague JE; Smolkin ME; Chianese-Bullock KA; Clark RA; Petroni GR; Marincola FM; Mullins DW; Slingluff CL
Cancer Immunol Immunother; 2016 Oct; 65(10):1201-12. PubMed ID: 27522582
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.
Meneveau MO; Petroni GR; Salerno EP; Lynch KT; Smolkin M; Woodson E; Chianese-Bullock KA; Olson WC; Deacon D; Patterson JW; Grosh WW; Slingluff CL
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035112
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of imiquimod skin penetration.
Telò I; Pescina S; Padula C; Santi P; Nicoli S
Int J Pharm; 2016 Sep; 511(1):516-523. PubMed ID: 27452419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
